Lupin Appoints Brian Savage as President and Chief Legal Officer
New Delhi: Global pharma major Lupin Limited (Lupin) announced the appointment of Brian Savage as President, Chief Legal Officer. Brian will lead Lupin's global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions, and will be based in New Jersey.
Brian joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva’s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva’s global litigation strategy and served as General Counsel for its U.S. Generics business. Prior to joining Teva, Brian practiced law at Dechert LLP.
Brian brings extensive experience navigating the complex legal and regulatory landscape in the global pharmaceutical industry. He holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania.
Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, “We are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.”
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 6 research centers globally, along with a dedicated workforce of over 26,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.